T1000	Speculation 2623 2630	propose
E1000	Speculation:T1000 Scope:T1001
T1001	Span 2623 2672	propose the designation myeloid/NK acute leukemia
T1002	Speculation 2516 2519	may
E1001	Speculation:T1002 Scope:T1003
T1003	Span 2516 2613	may arise from transformation of a precursor cell common to both the myeloid and NK cell lineages
T1004	Negation 911 913	no
E1002	Negation:T1004 Scope:T1005
T1005	Span 911 957	no case expressed CD2, CD3, or CD8 and no case
T1006	Speculation 122 133	potentially
E1003	Speculation:T1006 Scope:T1007
T1007	Span 122 213	potentially misdiagnosed as French-American-British acute myeloid leukemia-M3 [see comments
T1008	Negation 1488 1494	lacked
E1004	Negation:T1008 Scope:T1009
T1009	Span 1488 1628	lacked the promyelocytic/retinoic acid receptor alpha (RAR alpha) fusion transcript in RT-PCR assays; 12 cases had 46,XX or 46,XY karyotypes
T1010	Negation 950 952	no
E1005	Negation:T1010 Scope:T1011
T1011	Span 950 1048	no case showed clonal rearrangement of genes encoding the T-cell receptor (TCR beta, gamma, delta)
T1012	Negation 2015 2018	not
E1006	Negation:T1012 Scope:T1013
T1013	Span 2015 2052	not shown a clinical response to ATRA
T1014	Negation 1871 1877	failed
E1007	Negation:T1014 Scope:T1015
T1015	Span 1871 1949	failed to differentiate in vitro in response to all-trans retinoic acid (ATRA)
T1016	Speculation 1979 1982	may
E1008	Speculation:T1016 Scope:T1017
T1017	Span 1979 2052	may account for some APLs that have not shown a clinical response to ATRA
T1018	Speculation 1951 1961	suggesting
E1009	Speculation:T1018 Scope:T1019
T1019	Span 1951 2052	suggesting that these cases may account for some APLs that have not shown a clinical response to ATRA
T1020	Speculation 2475 2482	suggest
E1010	Speculation:T1020 Scope:T1021
T1021	Span 2475 2613	suggest that this form of acute leukemia may arise from transformation of a precursor cell common to both the myeloid and NK cell lineages
T1022	Speculation 2126 2136	suggesting
E1011	Speculation:T1022 Scope:T1023
T1023	Span 2126 2251	suggesting a relationship between these unique CD33+, CD56+, CD16- acute leukemias and normal CD56+, CD16- NK precursor cells
